PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY ROA Market segmentation by RoA Comparison by RoA Oral therapy - Market size and forecast 2018-2023 Intravenous therapy - Market size and forecast 2018-2023 Market opportunity by RoA PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Biocon Ltd. Intas Pharmaceuticals Ltd. Novartis AG Pfizer Inc. Zydus Cadila PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: RoA - Market share 2018-2023 (%) Exhibit 18: Comparison by RoA Exhibit 19: Oral therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Oral therapy - Year-over-year growth 2019-2023 (%) Exhibit 21: Pipeline molecules with oral RoA Exhibit 22: Intravenous therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Intravenous therapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by RoA Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: New cases of cancer in US: 2015 Exhibit 43: Alternative therapies for oncology indications for which mTOR inhibitors are used Exhibit 44: Side effects of mTOR inhibitors Exhibit 45: Impact of drivers and challenges Exhibit 46: Approved drugs with respect to their cancer indications Exhibit 47: Expansion of research areas of mTOR inhibitors Exhibit 48: Patient assistance programs Exhibit 49: Vendor landscape Exhibit 50: Landscape disruption Exhibit 51: Vendors covered Exhibit 52: Vendor classification Exhibit 53: Market positioning of vendors Exhibit 54: Biocon Ltd. - Vendor overview Exhibit 55: Biocon Ltd. - Business segments Exhibit 56: Biocon Ltd. - Organizational developments Exhibit 57: Biocon Ltd. - Geographic focus Exhibit 58: Biocon Ltd. - Segment focus Exhibit 59: Biocon Ltd. - Key offerings Exhibit 60: Biocon Ltd. - Key customers Exhibit 61: Intas Pharmaceuticals Ltd. - Vendor overview Exhibit 62: Intas Pharmaceuticals Ltd. - Business segments Exhibit 63: Intas Pharmaceuticals Ltd. - Organizational developments Exhibit 64: Intas Pharmaceuticals Ltd. - Key offerings Exhibit 65: Intas Pharmaceuticals Ltd. - Key customers Exhibit 66: Novartis AG - Vendor overview Exhibit 67: Novartis AG - Business segments Exhibit 68: Novartis AG - Organizational developments Exhibit 69: Novartis AG - Geographic focus Exhibit 70: Novartis AG - Segment focus Exhibit 71: Novartis AG - Key offerings Exhibit 72: Novartis AG - Key customers Exhibit 73: Pfizer Inc. - Vendor overview Exhibit 74: Pfizer Inc. - Business segments Exhibit 75: Pfizer Inc. - Organizational developments Exhibit 76: Pfizer Inc. - Geographic focus Exhibit 77: Pfizer Inc. - Segment focus Exhibit 78: Pfizer Inc. - Key offerings Exhibit 79: Pfizer Inc. - Key customers Exhibit 80: Zydus Cadila - Vendor overview Exhibit 81: Zydus Cadila - Business segments Exhibit 82: Zydus Cadila - Organizational developments Exhibit 83: Zydus Cadila - Geographic focus Exhibit 84: Zydus Cadila - Key offerings Exhibit 85: Zydus Cadila - Key customers Exhibit 86: Validation techniques employed for market sizing Exhibit 87: Definition of market positioning of vendors

Biocon Ltd. Intas Pharmaceuticals Ltd. Novartis AG Pfizer Inc. Zydus Cadila